选择性COX-2抑制剂塞来昔布抗癌作用研究进展  

Application of selective COX-2 inhibitors in the study of multi-drug-resistance

作　　者：李根[1] 陈虹[1] 

机构地区：[1]武警后勤学院生药学教研室,天津300162

出　　处：《武警医学院学报》2012年第3期214-216,220,共4页Acta Academiae Medicinae CPAPF

摘　　要：选择性COX-2抑制剂塞来昔布(celecoxib)作为一种新型NSAIDs,是一种高选择性环氧化酶抑制剂,由于其靶向性强、副作用小,已在多种肿瘤预防和治疗中发挥作用,近年来发现celecoxib可以增加抗癌药物浓度,降低甚至逆转对抗癌药物的耐药性,增强细胞对化疗药物的敏感性的作用,增强常规化疗疗效,同时塞来昔布对放疗也有一定的增敏作用。Selective COX-2 inhibitor celecoxib as a new type of NSAIDs,is a highly selective cyclooxygenase inhibitor.Ouingto its strong targeting and fewer side effects,it has been play a role in a variety of cancer prevention and treatment.In recent years it was found that celecoxib may increase the anti-cancer drug concentration,reduce or even reverse the anti-cancer drug resistance and enhance cellular sensitivity to chemotherapeutic drugs,enhancing the efficacy of conventional chemotherapy,and it also has some sensitizing effect on radiotherapy.

关 键 词：COX-2 塞来昔布 MDR 副作用 

分 类 号：R694.4[医药卫生—泌尿科学]